Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases

Boda-Heggemann, Judit ; Frauenfeld, Anian ; Weiss, Christel ; Simeonova, Anna ; Neumaier, Christian ; Siebenlist, Kerstin ; Attenberger, Ulrike ; Heußel, Claus Peter ; Schneider, Frank ; Wenz, Frederik ; Lohr, Frank

In: Radiation Oncology, 9 (2014), Nr. 10. pp. 1-9. ISSN 1748-717X

[thumbnail of 13014_2013_Article_1211.pdf]
Preview
PDF, English
Download (463kB) | Lizenz: Creative Commons LizenzvertragClinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases by Boda-Heggemann, Judit ; Frauenfeld, Anian ; Weiss, Christel ; Simeonova, Anna ; Neumaier, Christian ; Siebenlist, Kerstin ; Attenberger, Ulrike ; Heußel, Claus Peter ; Schneider, Frank ; Wenz, Frederik ; Lohr, Frank underlies the terms of Creative Commons Attribution 3.0 Germany

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: Stereotactic Ablative RadioTherapy (SABR) of lung tumors/metastases has been shown to be an effective treatment modality with low toxicity. Outcome and toxicity were retrospectively evaluated in a unique single-institution cohort treated with intensity-modulated image-guided breath-hold SABR (igSABR) without external immobilization. The dose–response relationship is analyzed based on Biologically Equivalent Dose (BED). Patients and methods: 50 lesions in 43 patients with primary NSCLC (n = 27) or lung-metastases of various primaries (n = 16) were consecutively treated with igSABR with Active-Breathing-Coordinator (ABC®) and repeat-breath-hold cone-beam-CT. After an initial dose-finding/-escalation period, 5x12 Gy for peripheral lesions and single doses of 5 Gy to varying dose levels for central lesions were applied. Overall-survival (OS), progression-free-survival (PFS), progression pattern, local control (LC) and toxicity were analyzed. Results: The median BED2 was 83 Gy. 12 lesions were treated with a BED2 of &lt;80 Gy, and 38 lesions with a BED2 of <80 Gy. Median follow-up was 15 months. Actuarial 1- and 2-year OS were 67% and 43%; respectively. Cause of death was non-disease-related in 27%. Actuarial 1- and 2-year PFS was 42% and 28%. Progression site was predominantly distant. Actuarial 1- and 2 year LC was 90% and 85%. LC showed a trend for a correlation to BED2 (p = 0.1167). Pneumonitis requiring conservative treatment occurred in 23%. Conclusion: Intensity-modulated breath-hold igSABR results in high LC-rates and low toxicity in this unfavorable patient cohort with inoperable lung tumors or metastases. A BED2 of <80 Gy was associated with reduced local control.

Document type: Article
Journal or Publication Title: Radiation Oncology
Volume: 9
Number: 10
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 22 Dec 2015 09:44
Date: 2014
ISSN: 1748-717X
Page Range: pp. 1-9
Faculties / Institutes: Medizinische Fakultät Mannheim > Institut für Klinische Radiologie
Medizinische Fakultät Mannheim > Medizinische Statistik, Biomathematik und Informationsverarbeitung
Medizinische Fakultät Mannheim > Klinik für Strahlentherapie und Radioonkologie
Medizinische Fakultät Heidelberg > Thoraxklinik Heidelberg gGmbH
DDC-classification: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative